Please login to the form below
Halaven
This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.
NICE set to reject wider use of Eisai’s Halaven
Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... NICE agreed last year that Halaven should be made
Latest news
-
NICE backs Eisai's Halaven for breast cancer
NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug. ... Halaven is one of Eisai's key growth products, accounting for 18.6bn yen ($181m) in sales in the first half of this fiscal year
-
Lilly closes on first approval for sarcoma drug Lartruvo
If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
-
Eisai gets green light for Lenvima in kidney cancer
Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
-
Oncology directions
Halaven (eribulin).
-
Disappointment for pharma with new Cancer Drugs Fund list
While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster
More from news
Approximately 8 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who are
-
Country report: The healthcare market in Japan
The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
